NGNE Neurogene Inc.

NASDAQ
$28.31

Neurogene Inc. (NGNE) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $1.39 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -21.8% since its last earnings release on August 11, 2026.

Neurogene Inc. Missed Consensus Estimates
Tuesday, August 11, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · After Close
Earnings Whisper
-
vs ($1.39)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $35.44

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Neurogene Inc.

Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.